



Patient Care + Research + Clinical Trials

**Dr. Tom Elliott MBBS, FRCPC**  
**Medical Director**

400 - 210 W Broadway phone: 604.683.3734  
Vancouver, BC fax: 604.628.3821  
V5Y 3W2 Canada email: drtomelliott@bcdiabetes.ca

2025-Oct-01

## **teplizumab “TzielD” treatment for early Type 1 diabetes**

On 2025-May-5 Health Canada approved of teplizumab branded as “TzielD” manufactured by Sanofi Canada, for the treatment of stage 2 Type 1 diabetes (T1D).

The Health Canada application was based on a series of papers including the following,

original paper = <https://www.nejm.org/doi/full/10.1056/NEJMoa1902226>

and the 2023 update of the original paper = <https://doi.org/10.2337/dc23-0675>,

For individuals with stage 2 T1D (see definition below) who received a single 14 day course of teplizumab [per protocol](#) the literature supports a delay of approximately 2 years in the development of stage 3 (clinical) T1D. [Delgado’s 2024 update](#) showed that 36% of individuals who received teplizumab remained clinically diabetes free at 5 years.

TzielD is available for prescription but not through regular Pharmacy channels, rather through [shield](#), a patient support program (PSP) that supplies TzielD and arranges infusion of TzielD. Here is a blank [shield PSP](#) application form. The first TzielD infusion in Canada was administered to a BCDiabetes client 2025-Sep-29. BCDiabetes recommends insertion of a [midline catheter](#) to minimize IV requirements. [Click here](#) for BCDiabetes routine premedication & infusion related bloodwork orders. Qualified individuals will receive TzielD at no cost. The retail cost of a 14 day infusion of TzielD is expected to be CAD\$250,000. Private and eventually public coverage for TzielD is expected in time.

### **TzielD protocol:**

teplizumab is given according to the [Heath Canada product monograph](#) IV over 30+ minutes daily for 14 days.

**TzielD** is indicated for individuals aged >8.0 years to delay the onset of stage 3 T1D (full-blown T1), with

**Confirmed stage 2 T1D** which requires both

two or more positive islet cell autoantibodies: anti-GAD65, anti-ICA512, anti-insulin (IAA), anti-ZnT8, and/or ICA. **No-cost autoantibody fingerpoke screening for all Canadians is now available.** BCDiabetes tested its first client July 22 and offers no-cost autoAb testing to the public for ages >8 years on a drop-in basis Tuesdays and Thursdays 09:00-16:00 hrs.

**AND**

dysglycemia- at least two of the following, or meeting the same single criteria at two time points within 12 months:

- Fasting glucose 5.6-6.9 mmol/L
- 2-hour post meal glucose 7.8-11.0 mmol/L
- 30, 60, 90-min post meal glucose  $\geq$  11.1 mmol/L
- A1C 5.7-6.4%, or  $\geq$ 10% increase from baseline

### **Safety testing:**

All individuals must be clinically well without suspicion of EBV or CMV & get these labs done.

CBC, differential and absolute neutrophil count

ALT, AST, bilirubin, HIV, anti-HCV, HBsAg, anti-HBs, and anti-HBc

[Here is a Lifelabs form with the necessary testing checked off.](#)

Short URL = <https://bit.ly/Tziel>